drugset / Trial / NCT01657071

Comparative Pharmacokinetics of YH14659 in Healthy Male Subjects

NCT01657071

Phase 1 Completed 60 enrolled Yuhan Corporation
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of this study is to compare pharmacokinetics after single oral administration of 2 capsules of YH14659, a fixed-dose combination of clopidogrel and aspirin developed by Yuhan Corporation versus co-administration of Plavix (clopidogrel) and Astrix (aspirin) in healthy male volunteers.

Timeline

Start
2012-03
Primary completion
2012-04
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 100 mg Oral
Comparator Clopidogrel Small molecule 75 mg Oral
Subject YH14659 Unknown Oral